Feature|Articles|December 27, 2023

Top Marketing Stories of 2023

Author(s)Mike Hollan

Pharma marketing teams had to deal with big changes in 2023.

Q&A With UCB's Camille Lee on New Psoriasis Medication Approval

The UCB executive speaks on recent FDA approval of Bimzelx.

Artificial Intelligence Changing the Landscape for Healthcare Social Media Marketing

Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence.

Fortifying Defenses Pre-Patent Cliff

Integrating artificial intelligence and advanced analytics throughout operations offers pharma companies a pathway to offset impending drug patent expirations.

Strategies for Success in an Evolving Commercialization Landscape

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Embracing Programmatic Advertising to Enhance Targeting of HCPs

The precision of programmatic advertising is reshaping the way life sciences brands engage with healthcare professionals, offering enhanced personalization, scale, and optimization in today's digital landscape.

Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.